Introduction There is limited real-world evidence regarding clinical practice for chronic
obstructive pulmonary disease (COPD) in Singapore. We compared baseline clinical …

Introduction This study aimed to characterize patients with chronic obstructive pulmonary
disease (COPD) newly prescribed a long-acting bronchodilator (LABD), and to assess …

Purpose Long-acting bronchodilator (LABD) use is the mainstay of pharmacologic treatment
for chronic obstructive pulmonary disease (COPD). Few studies describe evolving patterns …

Background Inhaled bronchodilators including long-acting beta-agonist (LABA) and long-
acting muscarinic antagonist (LAMA) play a central role in the treatment of stable chronic …

Abstract The Global Initiative for Chronic Obstructive Lung Disease (GOLD)
recommendations for the initial bronchodilator to use in newly diagnosed chronic obstructive …

Study Objective Inhaled long‐acting bronchodilators are commonly used as maintenance
therapy in chronic obstructive pulmonary disease (COPD). We compared the risk of …

Introduction Several dual bronchodilator fixed‐dose inhaler medications were recently
approved for the treatment of chronic obstructive pulmonary disease (COPD). These …

Background: Randomized clinical trials have shown long-acting mono bronchodilator
therapy to be efficacious in improving lung function and dyspnea, while reducing …

Background: Single-inhaler LAMA/LABA is recommended by the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) as maintenance therapy for patients with COPD, but the …

Background To estimate the potential cost savings by following the current Global Initiative
for Chronic Obstructive Lung Disease (GOLD) guideline recommendations in patients being …